Home > Oncology > Proton-pump inhibitors may reduce benefits of atezolizumab in urothelial carcinoma

Proton-pump inhibitors may reduce benefits of atezolizumab in urothelial carcinoma

Journal
Clinical Cancer Research
Reuters Health - 23/09/2020 - The use of proton-pump inhibitors (PPIs) is associated with worse overall survival in patients with urothelial carcinoma treated with the immune-checkpoint inhibitor (ICI) atezolizumab, but not in those treated with chemotherapy, according to a retrospective study. "The magnitude of the reduction in atezolizumab benefit associated with concomitant PPI use was the most surprising result," said Dr. Ashley M. Hopkins of the College of Medicine and Public Health at Flinders University, in Adelaide, Australia. These results, he told Reuters Health by email, "represent an urgent need to establish if the PPI impact is specific to atezolizumab, urothelial carcinoma, or immunotherapies more generally." PPIs alter the gut microbiota, and previous studies investigating the influence of PPIs on ICIs have yielded conflicting results. No studies have investigated the association between PPI use and survival outcomes with ICIs in patients with ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on